Inhibition and inactivation of liver aldolase
dc.contributor.author | Waud, John | en_US |
dc.contributor.author | Feldman, Ellen | en_US |
dc.contributor.author | Schray, Keith | en_US |
dc.date.accessioned | 2006-08-29T18:33:57Z | en_US |
dc.date.available | 2006-08-29T18:33:57Z | en_US |
dc.date.issued | 1981-02 | en_US |
dc.identifier.citation | Archives of Biochemistry and Biophysics 206N2 (1981) 291-295 | en_US |
dc.identifier.issn | 0003-9861 | en_US |
dc.identifier.uri | http://hdl.handle.net/1850/2562 | en_US |
dc.description.abstract | Substrate analogs xylulose 1,5-bisphosphate, glucitol 1,6-bisphosphate, alpha-2,5-anhydroglucitol 1,6-bisphosphate, alpha-, beta-methyl fructofuranoside 1,6-bisphosphate, ribulose 1,5-bisphosphate, ribulose 5-phosphate, and ribose 5-phosphate and inactivating agents 1-chloro-2, 4-dinitrobenzene, 4-hydroxymercuribenzoate, and pyridoxal phosphate were examined for their effects on liver aldolase. These studies support the use of the beta-anomer and acyclic form as substrate. They also suggest that the liver enzyme active site is similar to the muscle enzyme but with a much weaker 6-phosphate binding site. | en_US |
dc.description.sponsorship | This investigation was supported by U. S. Public Health Service Research Grant GM-22378 and a Biomedical Support Grant S07 RR 07173. | en_US |
dc.format.extent | 37365 bytes | en_US |
dc.format.mimetype | application/pdf | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier: Archives of Biochemistry and Biophysics | en_US |
dc.subject | Inactivation | en_US |
dc.subject | Liver aldolase | en_US |
dc.subject | Liver enzymes | en_US |
dc.title | Inhibition and inactivation of liver aldolase | en_US |
dc.type | Article | en_US |
dc.identifier.url | http://dx.doi.org/10.1016/0003-9861(81)90094-1 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |